Home
http://www.spacedoc.com/Statins-Diabetes-Heart-Failure-Rhabdomyolysis-Kidney-Disease?utm_source=January%2012,%202014&utm_campaign=Jan%202014%20Newsletter&utm_medium=email
It is now becoming realized that myopathy, the most common adverse reaction of statin drug use, is a major cause of kidney tubular blockade. Even a localized myopathic process can be associated with sufficient inflammatory response to trigger muscle cell wall breakdown releasing minute cellular fragments to lodge in kidney tubules causing progressive kidney damage. With the myopathy incidence now estimated at 20 percent, there is reason to believe that myopathy is a major contributor to CKD.
In the past 6 years, 9,111 cases of statin associated rhabdomyolysis have been reported to FDA's Medwatch for an estimated 911 deaths. We are now in the midst of a rapidly growing epidemic of statin associated rhabdomyolysis.
It is now becoming realized that myopathy, the most common adverse reaction of statin drug use, is a major cause of kidney tubular blockade. Even a localized myopathic process can be associated with sufficient inflammatory response to trigger muscle cell wall breakdown releasing minute cellular fragments to lodge in kidney tubules causing progressive kidney damage. With the myopathy incidence now estimated at 20 percent, there is reason to believe that myopathy is a major contributor to CKD.
In the past 6 years, 9,111 cases of statin associated rhabdomyolysis have been reported to FDA's Medwatch for an estimated 911 deaths. We are now in the midst of a rapidly growing epidemic of statin associated rhabdomyolysis.